TABLE 3.
Baseline medications grouped by ATC group and inter-group differences.
| ATC group | Total N = 1252 | DRAs n = 195 | DRAs related to | non-DRAs n = 1057 | DRAs related to safety | ||
|---|---|---|---|---|---|---|---|
| Treatment effectiveness n = 50 | Treatment safety n = 145 | Preventable n = 50 | Non-preventable n = 95 | ||||
| Diuretics | 58% | 90% | 92% | 89% | 52% | 70% | 99% |
| Antithrombotic agents | 53% | 78% | 52% | 88% | 48% | 84% | 89% |
| Agents acting on the renin-angiotensin system | 40% | 43% | 40% | 44% | 40% | 44% | 44% |
| Drugs used in diabetes | 36% | 51% | 60% | 48% | 33% | 46% | 48% |
| Beta blocking agents | 35% | 44% | 34% | 48% | 33% | 42% | 51% |
| Drugs for obstructive airway diseases | 32% | 32% | 30% | 32% | 33% | 16% | 41% |
| Lipid modifying agents | 32% | 35% | 28% | 37% | 32% | 34% | 39% |
| Drugs for acid related disorders | 30% | 46% | 26% | 52% | 27% | 48% | 55% |
| Analgesics | 23% | 39% | 8% | 50% | 20% | 50% | 51% |
| Calcium channel blockers | 22% | 25% | 16% | 28% | 22% | 32% | 25% |
| Psychoanaleptics | 22% | 27% | 28% | 26% | 21% | 24% | 27% |
| Psycholeptics | 21% | 27% | 16% | 30% | 20% | 44% | 23% |
| Mineral supplements | 16% | 24% | 10% | 29% | 15% | 22% | 33% |
| Antigout preparations | 15% | 19% | 6% | 24% | 14% | 20% | 26% |
| Cardiac therapy | 13% | 26% | 16% | 29% | 11% | 16% | 36% |
| Urologicals | 13% | 19% | 14% | 21% | 11% | 16% | 23% |
| Thyroid therapy | 12% | 14% | 4% | 17% | 12% | 18% | 17% |
| Vitamins | 12% | 18% | 14% | 19% | 11% | 12% | 23% |
| Antiepileptics | 8% | 14% | 6% | 17% | 7% | 18% | 16% |
| Vasoprotectives | 7% | 10% | 6% | 11% | 7% | 16% | 8% |
| Anti-inflammatory and antirheumatic products | 7% | 14% | 10% | 16% | 6% | 32% | 7% |
| Antihypertensives | 6% | 8% | 4% | 10% | 5% | 14% | 7% |
| Antianemic preparations | 6% | 9% | 10% | 8% | 5% | 8% | 8% |
| Drugs for functional gastrointestinal disorders | 6% | 11% | 6% | 12% | 5% | 10% | 14% |
| Corticosteroids for systemic use | 5% | 13% | 4% | 16% | 4% | 4% | 22% |
| Antineoplastic agents | 5% | 18% | 0% | 25% | 2% | 4% | 36% |
| Antihistamines for systemic use | 5% | 8% | 4% | 9% | 4% | 4% | 12% |
| Ophthalmologicals | 5% | 6% | 0% | 8% | 4% | 8% | 7% |
| Laxatives | 3% | 4% | 0% | 6% | 3% | 6% | 5% |
| Immunosuppressants | 3% | 7% | 4% | 8% | 2% | 2% | 12% |
| Cough and cold preparations | 3% | 4% | 0% | 5% | 2% | 0% | 7% |
| Anti-parkinson drugs | 2% | 5% | 4% | 6% | 2% | 6% | 5% |
| Other nervous system drugs | 2% | 0% | 0% | 0% | 3% | 0% | 0% |
| Antidiarrheals, intestinal antiinflammatory/antiinfective agents | 2% | 6% | 6% | 6% | 2% | 4% | 6% |
| Drugs for treatment of bone diseases | 2% | 2% | 0% | 2% | 2% | 4% | 1% |
DRA, Drug-related hospital admission; ATC: Anatomical Therapeutic Chemical.
Note: Medication classes with <2% prevalence were omitted from this table for readability.